Avecho Biotechnology Limited
ASX: AVE.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Paul Gavin
- Employees
- 29
- Headquarters
- Clayton, Australia
- IPO year
- 1999
- Market cap
- A$38.6M
- Website
- https://avecho.com.au
Loading AVE…
Loading profile data…Frequently asked questions about AVE
What does Avecho Biotechnology Limited (AVE.AX) do?
Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulat...
Where does AVE.AX trade?
Avecho Biotechnology Limited (AVE.AX) trades on the Australian Securities Exchange.
What sector is AVE.AX in?
Avecho Biotechnology Limited (AVE.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Avecho Biotechnology Limited?
Paul Gavin is the chief executive officer of Avecho Biotechnology Limited (AVE.AX).
Where is Avecho Biotechnology Limited headquartered?
Avecho Biotechnology Limited is headquartered in Australia.
Does AVE.AX pay a dividend?
Avecho Biotechnology Limited (AVE.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AVE.AX go public?
Avecho Biotechnology Limited (AVE.AX) completed its initial public offering in 1999.